BioSpace News Archive

Aethlon Medical, Inc. (Nasdaq:AEMD) (the “Company”), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 1,885,378 shares of its common stock,

PANTHERx® Rare Pharmacy announces that it has been selected by Blueprint Medicines Corporation as a very limited distribution partner for breakthrough drug AYVAKIT™ (avapritinib)

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that the Company recognized significant growth across the business in 2019.

Technavio has announced its latest market research report titled global bathroom and toilet assist devices market 2019-2023.

AMPEL BioSolutions’ Co-Founder and COO/CSO Dr. Amrie Grammer today at the Biotech Showcase at JP Morgan Healthcare announces the kickoff of a Series A $12.5M raise to commercialize LuGENETM, a gene-based diagnostic.

Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that a leading proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that shareholders vote on the BLUE proxy card in support of HDF’s nominee, Fabian Blank.

Technavio has announced its latest market research report titled global epidermolysis bullosa therapeutics market 2019-2023.

Sygnature Discovery has further strengthened its DMPK (drug metabolism and pharmacokinetics) capabilities, with the addition of new senior scientists to the management team.

Halo Labs Inc. (“Halo” or the “Company”) (OTCQX:AGEEF), wishes to make the following statements regarding recent market activity concerning its common shares (the “Common Shares”) traded on the OTCQX marketplace.

CytomX Therapeutics, Inc. announced that on January 15, 2020, the Company granted three new employees options to purchase a total of 44,600 shares of the Company’s common stock at an exercise price per share equal to $7.82, which was the closing trading price on January 15, 2020, the date of the grant.